Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant
ABSTRACTBackground Heterologous prime-boost schedules have been employed in SARS-CoV-2 vaccination, yet additional data on immunogenicity and effectiveness are still needed.Research design and methods Here, we measured the immunogenicity and effectiveness in the real-world setting of the mRNA booste...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2333952 |
| _version_ | 1797226218510090240 |
|---|---|
| author | Gabiria Pastore Jacopo Polvere Fabio Fiorino Simone Lucchesi Giorgio Montesi Ilaria Rancan Sara Zirpoli Arianna Lippi Miriam Durante Massimiliano Fabbiani Mario Tumbarello Francesca Montagnani Donata Medaglini Annalisa Ciabattini |
| author_facet | Gabiria Pastore Jacopo Polvere Fabio Fiorino Simone Lucchesi Giorgio Montesi Ilaria Rancan Sara Zirpoli Arianna Lippi Miriam Durante Massimiliano Fabbiani Mario Tumbarello Francesca Montagnani Donata Medaglini Annalisa Ciabattini |
| author_sort | Gabiria Pastore |
| collection | DOAJ |
| description | ABSTRACTBackground Heterologous prime-boost schedules have been employed in SARS-CoV-2 vaccination, yet additional data on immunogenicity and effectiveness are still needed.Research design and methods Here, we measured the immunogenicity and effectiveness in the real-world setting of the mRNA booster dose in 181 subjects who had completed primary vaccination with ChAdOx1, BNT162b2, or mRNA1273 vaccines (IMMUNO_COV study; protocol code 18,869). The spike-specific antibody and B cell responses were analyzed up to 6 months after boosting.Results After an initial slower antibody response, the heterologous ChAdOx1/mRNA prime-boost formulation elicited spike-specific IgG titers comparable to homologous approaches, while spike-specific B cells showed a higher percentage of CD21−CD27− atypical cells compared to homologous mRNA vaccination. Mixed combinations of BNT162b2 and mRNA-1273 elicited an immune response comparable with homologous strategies. Non-significant differences in the Relative Risk of infection, calculated over a period of 18 months after boosting, were reported among homologous or heterologous vaccination groups, indicating a comparable relative vaccine effectiveness.Conclusions Our data endorse the heterologous booster vaccination with mRNA as a valuable alternative to homologous schedules. This approach can serve as a solution in instances of formulation shortages and contribute to enhancing vaccine strategies for potential epidemics or pandemics. |
| first_indexed | 2024-04-24T14:21:25Z |
| format | Article |
| id | doaj.art-57414c1aeb95453cac2578ec49079d8f |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-04-24T14:21:25Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-57414c1aeb95453cac2578ec49079d8f2024-04-03T06:38:02ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952024-12-0123143244410.1080/14760584.2024.2333952Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variantGabiria Pastore0Jacopo Polvere1Fabio Fiorino2Simone Lucchesi3Giorgio Montesi4Ilaria Rancan5Sara Zirpoli6Arianna Lippi7Miriam Durante8Massimiliano Fabbiani9Mario Tumbarello10Francesca Montagnani11Donata Medaglini12Annalisa Ciabattini13Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, ItalyLaboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, ItalyLaboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, ItalyLaboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, ItalyLaboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, ItalyDepartment of Medical Biotechnologies, University of Siena, Siena, ItalyLaboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, ItalyDepartment of Medical Biotechnologies, University of Siena, Siena, ItalyDepartment of Medical Biotechnologies, University of Siena, Siena, ItalyDepartment of Medical Biotechnologies, University of Siena, Siena, ItalyDepartment of Medical Biotechnologies, University of Siena, Siena, ItalyDepartment of Medical Biotechnologies, University of Siena, Siena, ItalyLaboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, ItalyLaboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, ItalyABSTRACTBackground Heterologous prime-boost schedules have been employed in SARS-CoV-2 vaccination, yet additional data on immunogenicity and effectiveness are still needed.Research design and methods Here, we measured the immunogenicity and effectiveness in the real-world setting of the mRNA booster dose in 181 subjects who had completed primary vaccination with ChAdOx1, BNT162b2, or mRNA1273 vaccines (IMMUNO_COV study; protocol code 18,869). The spike-specific antibody and B cell responses were analyzed up to 6 months after boosting.Results After an initial slower antibody response, the heterologous ChAdOx1/mRNA prime-boost formulation elicited spike-specific IgG titers comparable to homologous approaches, while spike-specific B cells showed a higher percentage of CD21−CD27− atypical cells compared to homologous mRNA vaccination. Mixed combinations of BNT162b2 and mRNA-1273 elicited an immune response comparable with homologous strategies. Non-significant differences in the Relative Risk of infection, calculated over a period of 18 months after boosting, were reported among homologous or heterologous vaccination groups, indicating a comparable relative vaccine effectiveness.Conclusions Our data endorse the heterologous booster vaccination with mRNA as a valuable alternative to homologous schedules. This approach can serve as a solution in instances of formulation shortages and contribute to enhancing vaccine strategies for potential epidemics or pandemics.https://www.tandfonline.com/doi/10.1080/14760584.2024.2333952COVID-19 vaccinationheterologous and homologous vaccinationprime-boostSARS-CoV-2vaccination strategies |
| spellingShingle | Gabiria Pastore Jacopo Polvere Fabio Fiorino Simone Lucchesi Giorgio Montesi Ilaria Rancan Sara Zirpoli Arianna Lippi Miriam Durante Massimiliano Fabbiani Mario Tumbarello Francesca Montagnani Donata Medaglini Annalisa Ciabattini Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant Expert Review of Vaccines COVID-19 vaccination heterologous and homologous vaccination prime-boost SARS-CoV-2 vaccination strategies |
| title | Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant |
| title_full | Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant |
| title_fullStr | Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant |
| title_full_unstemmed | Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant |
| title_short | Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant |
| title_sort | homologous or heterologous administration of mrna or adenovirus vectored vaccines show comparable immunogenicity and effectiveness against the sars cov 2 omicron variant |
| topic | COVID-19 vaccination heterologous and homologous vaccination prime-boost SARS-CoV-2 vaccination strategies |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2024.2333952 |
| work_keys_str_mv | AT gabiriapastore homologousorheterologousadministrationofmrnaoradenovirusvectoredvaccinesshowcomparableimmunogenicityandeffectivenessagainstthesarscov2omicronvariant AT jacopopolvere homologousorheterologousadministrationofmrnaoradenovirusvectoredvaccinesshowcomparableimmunogenicityandeffectivenessagainstthesarscov2omicronvariant AT fabiofiorino homologousorheterologousadministrationofmrnaoradenovirusvectoredvaccinesshowcomparableimmunogenicityandeffectivenessagainstthesarscov2omicronvariant AT simonelucchesi homologousorheterologousadministrationofmrnaoradenovirusvectoredvaccinesshowcomparableimmunogenicityandeffectivenessagainstthesarscov2omicronvariant AT giorgiomontesi homologousorheterologousadministrationofmrnaoradenovirusvectoredvaccinesshowcomparableimmunogenicityandeffectivenessagainstthesarscov2omicronvariant AT ilariarancan homologousorheterologousadministrationofmrnaoradenovirusvectoredvaccinesshowcomparableimmunogenicityandeffectivenessagainstthesarscov2omicronvariant AT sarazirpoli homologousorheterologousadministrationofmrnaoradenovirusvectoredvaccinesshowcomparableimmunogenicityandeffectivenessagainstthesarscov2omicronvariant AT ariannalippi homologousorheterologousadministrationofmrnaoradenovirusvectoredvaccinesshowcomparableimmunogenicityandeffectivenessagainstthesarscov2omicronvariant AT miriamdurante homologousorheterologousadministrationofmrnaoradenovirusvectoredvaccinesshowcomparableimmunogenicityandeffectivenessagainstthesarscov2omicronvariant AT massimilianofabbiani homologousorheterologousadministrationofmrnaoradenovirusvectoredvaccinesshowcomparableimmunogenicityandeffectivenessagainstthesarscov2omicronvariant AT mariotumbarello homologousorheterologousadministrationofmrnaoradenovirusvectoredvaccinesshowcomparableimmunogenicityandeffectivenessagainstthesarscov2omicronvariant AT francescamontagnani homologousorheterologousadministrationofmrnaoradenovirusvectoredvaccinesshowcomparableimmunogenicityandeffectivenessagainstthesarscov2omicronvariant AT donatamedaglini homologousorheterologousadministrationofmrnaoradenovirusvectoredvaccinesshowcomparableimmunogenicityandeffectivenessagainstthesarscov2omicronvariant AT annalisaciabattini homologousorheterologousadministrationofmrnaoradenovirusvectoredvaccinesshowcomparableimmunogenicityandeffectivenessagainstthesarscov2omicronvariant |